Core Viewpoint - The approval of PB-119 by the National Medical Products Administration of China marks a significant milestone for the company, potentially enhancing its market position in the diabetes treatment sector [1] Company Summary - The stock of the company, Paigene Biopharmaceutical-B (02565), opened nearly 15% higher and is currently trading at 72.7 HKD, with a transaction volume of 1.1269 million HKD [1] - PB-119 is a new generation long-acting GLP-1 receptor agonist developed by the company, designed for weekly administration [1] - PB-119 has been recognized as a Class 1 new drug, categorized as a "major new drug creation" by the National Science and Technology Major Project [1] Product Summary - Clinical studies (Phase I to III) indicate that PB-119 achieves an optimal balance between effective blood sugar control and good tolerability, providing a high-efficiency and safe treatment option for type 2 diabetes patients in China [1] - PB-119 significantly improves β-cell function and offers comprehensive management of patients' blood pressure, blood lipids, and weight, achieving a "four highs co-management" approach for overall benefits [1]
派格生物医药-B高开近15% 核心产品PB-119新药上市申请获批